GSK and Cognizant aim to cut delays in drug-safety reviews, improve traceability and leave medical decisions to specialists.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results